Allergen-Specific Immunotherapy in Food Anaphylaxis

World Allergy Organization Journal

Johannes Ring²  Martin Mempel²  Regina Kerzl¹ 

[1] Department of Dermatology and Allergy, Biederstein, Technische Universität München (TUM), Munich, Germany;Division of Environmental Dermatology and Allergy GSF/TUM, GSF National Research Center for Environment and Health, Neuherberg, Germany

关键词: long-term effect;    food allergy;    allergen-specific immunotherapy;   

Others  :  825203
DOI  :  10.1097/WOX.0b013e318165b9c1

 received in 2007-10-05, accepted in 2007-12-18,  发布年份 2008

【 摘 要 】

Specific immunotherapy (SIT) protocols for nutritional allergens have only recently been established with a focus on oral allergy syndrome because of pollen cross-reacting antibodies. For these patients, a substantial number of studies have been published suggesting benefits from SIT. The situation in true anaphylaxis to food allergens such as peanut allergy is more complex, and therapeutic strategies are based on individual protocols rather than controlled studies. However, in defined cases, SIT represents a promising approach for a durable protection from life-threatening risks after accidental ingestion.

【 授权许可】

   
2012 World Allergy Organization; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mansueto P, Montalto G, Pacor ML, Esposito-Pellitteri M, Ditta V, Lo Bianco C, et al.: Food allergy in gastroenterologic diseases: review of literature. World J Gastroenterol 2006, 12:7744-7752.
• [2]Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558-562.
• [3]Tsitoura DC, Tassios Y: Immunomodulation: the future cure for allergic diseases. Ann N Y Acad Sci 2006, 1088:100-115.
• [4]Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119:780-791.
• [5]Rak S, Lowhagen O, Venge P: The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988, 82:470-480.
• [6]Halken S: Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004, 15(suppl 16):4-5. [9-32]
• [7]Borelli S, Anliker MD, Wuthrich B: Peanut anaphylaxis: the problem of hidden allergens. Dtsch Med Wochenschr 1999, 124:1197-1200.
• [8]Hozyasz K, Gajewska J, Ambroszkiewicz J: Hidden food allergens: peanut and glutenVin Polish foodstuffs. Pol Merkur Lekarski 2004, 17:374-377.
• [9]Schappi GF, Konrad V, Imhof D, Etter R, Wüthrich B: Hidden peanut allergens detected in various foods: findings and legal measures. Allergy 2001, 56:1216-1220.
• [10]Moingeon P: Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006, 61(suppl 81):15-19.
• [11]McEldowney SJ, Bush RK: Pollen immunotherapy: selection, prevention, and future directions. Curr Allergy Asthma Rep 2006, 6:420-426.
• [12]Bolhaar ST, Tiemessen MM, Zuidmeer L, van Leeuwen A, Hoffmann-Sommergruber K, Bruijnzeel-Koomen CA, et al.: Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004, 34:761-769.
• [13]Gonzalez EM, Villalba M, Rodriguez R: Allergenic cross-reactivity of olive pollen. Allergy 2000, 55:658-663.
• [14]Bousquet J, Cour P, Guerin B, Michel FB: Allergy in the Mediterranean area. I. Pollen counts and pollinosis of Montpellier. Clin Allergy 1984, 14:249-258.
• [15]Duffort O, Palomares O, Lombardero M, Villalba M, Barber D, et al.: Variability of Ole e 9 allergen in olive pollen extracts: relevance of minor allergens in immunotherapy treatments. Int Arch Allergy Immunol 2006, 140:131-138.
• [16]Florido JF, Delgado PG, de San Pedro BS, Quiralte J, de Saavedra JM, Peralta V, et al.: High levels of Olea europaea pollen and relation with clinical findings. Int Arch Allergy Immunol 1999, 119:133-137.
• [17]Fuiano N, Incorvaia C, Riario-Sforza GG, Casino G: Anaphylaxis to honey in pollinosis to mugwort: a case report. Allerg Immunol (Paris) 2006, 38:364-365.
• [18]Karakaya G, Fuat Kalyoncu A: Honey allergy in adult allergy practice. Allergol Immunopathol (Madr) 1999, 27:271-272.
• [19]Lombardi C, Senna GE, Gatti B, Feligioni M, Riva G, Bonadonna P, et al.: Allergic reactions to honey and royal jelly and their relationship with sensitization to compositae. Allergol Immunopathol (Madr) 1998, 26:288-290.
• [20]Barral P, Batanero E, Palomares O, Quiralte J, Villalba M, Rodriguez R: A major allergen from pollen defines a novel family of plant proteins and shows intra- and interspecies [correction of interspecie] cross-reactivity. J Immunol 2004, 172:3644-3651.
• [21]Palomares O, Villalba M, Quiralte J, Rodriguez R: Allergenic contribution of the IgE-reactive domains of the 1,3-beta-glucanase Ole e 9: diagnostic value in olive pollen allergy. Ann Allergy Asthma Immunol 2006, 97:61-65.
• [22]Gonzalez P, Florido F, Saenz B, de la Torre F, Rico P, Martin S: Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol 2002, 12:263-271.
• [23]Guerra F, Daza JC, Almeda E: Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol 2003, 13:108-117.
• [24]Rodriguez R, Villalba M, Monsalve RI, Batanero E: The spectrum of olive pollen allergens. Int Arch Allergy Immunol 2001, 125:185-195.
• [25]Palomares O, Batanero E, Canamero M, Villalba M, Rodriguez R: Prophylactic intranasal treatment with fragments of 1,3-beta-glucanase olive pollen allergen prevents airway inflammation in a murine model of type I allergy. Int Arch Allergy Immunol 2006, 139:175-180.
• [26]Ortolani C, Ispano M, Pastorello E, Bigi A, Ansaloni R: The oral allergy syndrome. Ann Allergy 1988, 61:47-52.
• [27]Pastorello EA, Incorvaia C, Ortolani C: Mechanisms in adverse reactions to food. The mouth and pharynx. Allergy 1995, 50:40-45.
• [28]Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, et al.: Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995, 95:962-969.
• [29]Inschlag C, Hoffmann-Sommergruber K, O'Riordain G, Ahorn H, Ebner C, Scheiner O, et al.: Biochemical characterization of Pru a 2, a 23-kD thaumatin-like protein representing a potential major allergen in cherry (Prunus avium). Int Arch Allergy Immunol 1998, 116:22-28.
• [30]Vanek-Krebitz M, Hoffmann-Sommergruber K, Laimer M, Susani M, Ebner C, et al.: Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. Biochem Biophys Res Commun 1995, 214:538-551.
• [31]Moneo I, Gomez M, Sanchez-Monge R, Alday E, de las Heras M, et al.: Lack of crossreaction with Bet v 1 in patients sensitized to Dau c 1, a carrot allergen. Ann Allergy Asthma Immunol 1999, 83:71-75.
• [32]Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK, Malling HJ: Food allergy to apple and specific immunotherapy with birch pollen. Mol Nutr Food Res 2004, 48:441-448.
• [33]Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C, et al.: Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007, 119:937-943.
• [34]Asero R: Effects of birch pollen-specific immunotherapy on apple allergy in birch pollenYhypersensitive patients. Clin Exp Allergy 1998, 28:1368-1373.
• [35]Bucher X, Pichler WJ, Dahinden CA, Helbling A: Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004, 59:1272-1276.
• [36]Mari A, Ballmer-Weber BK, Vieths S: The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 2005, 5:267-273.
• [37]Christie L, Hine RJ, Parker JG, Burks W: Food allergies in children affect nutrient intake and growth. J Am Diet Assoc 2002, 102:1648-1651.
• [38]Sampson HA: Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol 1999, 103:981-989.
• [39]Sicherer SH: The impact of maternal diets during breastfeeding on the prevention of food allergy. Curr Opin Allergy Clin Immunol 2002, 2:207-210.
• [40]Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CA, Pasmans SG: Acute allergic reactions in children with AEDS after prolonged cow's milk elimination diets. Allergy 2006, 61:370-374.
• [41]Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG: A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 2004, 59:980-987.
• [42]Bauer A, Ekanayake Mudiyanselage S, Wigger-Alberti W, Elsner P: Oral rush desensitization to milk. Allergy 1999, 54:894-895.
• [43]Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB: Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology 1998, 45:52-58.
• [44]Rank MA, Li JT: Allergen immunotherapy. Mayo Clin Proc 2007, 82:1119-1123.
• [45]Rolinck-Werninghaus C, Staden U, Mehl A, Hamelmann E, Beyer K, Niggemann B: Specific oral tolerance induction with food in children: transient or persistent effect on food allergy? Allergy 2005, 60:1320-1322.
• [46]Mansfield L: Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol 2006, 97:266-267.
• [47]Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY: Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992, 90:256-262.
• [48]Patriarca G, Nucera E, Pollastrini E, De Pasquale T, Lombardo C, et al.: Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci 2006, 51:471-473.
• [49]Mempel M, Rakoski J, Ring J, Ollert M: Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003, 111:1406-1409.
• [50]Kerzl R, Simonowa A, Ring J, Ollert M, Mempel M: Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol 2007, 119:507-508.
• [51]Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, et al.: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348:986-993.
• [52]Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, et al.: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117:134-140.
• [53]Nelson HS: Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2003, 111(suppl):S793-S797.
• [54]Passalacqua G, Canonica GW: Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy 2002, 57:275-276.